Nutrition is a viable function. 20-50% of all tumor patients present with reduced nutritional status before any therapy starts. Nevertheless mostly aggressive multimodal therapy is necessary, which further deteriorates the nutritional status. In palliative situations, if there is no further treatment option in advanced cancer, cachexia is the major cause of death. Therefore supportive nutritional therapy has two objectives: firstly to improve the nutritional status in patients suffering from tumor cachexia, a most controversial subject [1] , and secondly prevention of further deterioration due to radio(chemo)therapy. This second objective will be discussed here. In principle there are two different ways of artificial feeding: enteral or parenteral nutrition [2] . The advantages of enteral nutrition during radiotherapy will be shown by the results obtained in Erlangen and compared to the other possibilities of nutritional therapy.
Causes of Malnutrition of Cancer Patients
Nutrition is impaired by cancer disease for a variety of reasons, which can be divided generally into three main causes [3] :
Tumor-related: The tumor-induced obstruction of the upper digestive tract causes the patient to take in only semiliquid or liquid meals rich in carbohydrates, which eventually leads to the cessation of eating at all. Increased metabolism and energy consumption of the tumor occur. Patient-related: Many patients suffer from anorexia as a consequence of the central action of cytokines, tumor byproducts and the catabolic state due to metabolic abnormalities [4, 5] . But anorexia causes inadequate food intake.
Moreover patients with carcinomas of the upper aerodigestive system are partly obstinate excessive smokers and drinkers with bad eating habits, poor oral hygiene and a very bad dental status because of inadequate dental care. Therapy-related: Surgery, chemotherapy and radiotherapy are responsible for well-known side effects. In this context the effect of radiotherapy must be explained in more detail. Acute radiation reactions (Table 1) are frequent, usually inevitable and of limited duration. In contrast chronic radiation sequelae rarely occur, but in most cases they continue during the patient's whole life. The nutritional disorders caused by irradiation depend on: the type of irradiation; the single and end dose, fractionation and duration of radiotherapy; the region and volume irradiated, and the combination with other therapy modalities, especially chemotherapy applied concurrently with irradiation. Inadequate oral food intake is caused by mucositis, xerostomia, alterations in the sensation of smell and taste if the head and neck region is irradiated. Esophagitis can occur during radiotherapy of carcinomas of the lung or esophagus. Anorexia, nausea and vomiting can occur during irradiation of tumors of the brain or abdomen. Defective digestion, malabsorption and diarrhea can result if large portions of the small intestine and colon are irradiated. 
Effect of Enteral Nutrition during Radiotherapy of Patients with Head and Neck Tumors

Patients and Methods
In order to investigate the effect of enteral nutrition during and after radiotherapy, in January 1986 we started a prospective trial. A total of 212 patients with advanced tumors of the head and neck were included. 134/212 (63%) patients fed themselves orally with a normal diet or supplementary oral formula diets. In accordance with the protocol, 47/212 (22%) patients received percutaneous endoscopic gastrostomy (PEG) within 2 weeks after radiotherapy was started. Another 31 (15%) patients received the PEG later than this and were therefore not taken into account. In the following only the orally fed patients and the 47 PEG patients were compared. The nutritional status of the patients was determined by anthropometric, biochemical and immunological parameters before radiotherapy started, 2, 4 and 6 weeks later on during radiotherapy, and 6, 12 and 18 weeks after completion of radiotherapy. Moreover we studied the effects of enteral feeding via PEG on patients' quality of life by choosing the questionnaires originally developed by Padilla et al. [6] . A primarily planned randomized study was not feasible because a large number of our colleagues were so impressed by the good results provided by the enteral PEG feeding that they carried out PEG before radiotherapy was started. Randomization became impossible and the study was continued as an observation study.
As shown in the following the initial values of all measured parameters of the orally fed patients were clearly above those of the PEG patients. For better comparison we calculated relative values from the absolute values, i.e., the values at 2, 4 and 6 weeks after beginning the study were subtracted from the initial values. Negative values show a decrease, positive ones an increase in the parameters.
Results
Body weight was used as the parameter for body mass (Fig. 1) . The initial weight of the orally fed patients (mean 73 kg) was clearly above that (mean 62 kg) of the PEG patients. The orally fed patients experienced a mean weight loss of 2.5 kg during radiotherapy. In contrast the PEG patients gained on average 0.5 kg while therapy was still in progress. The difference at the end of therapy (6 weeks) is statistically different.
Upper arm muscle circumference was taken as a measurement of lean body mass. The initial values of the orally fed patients were markedly above those of the PEG patients, but in neither group did major alteration occur during or following therapy.
The triceps skinfold thickness (Fig. 2 ) was taken as an indicator of patients' fat reserves. For the orally fed patients the values dropped during radiotherapy, while the values of the PEG patients remained constant or increased slowly. We con- clude from the last three curves that the weight loss in the orally fed patients can probably be attributed to a decrease in their fat reserves. In contrast, the PEG patients kept their low fat reserves constant or began to replenish them during the radiotherapeutic course.
As markers for metabolic changes we investigated different visceral proteins with short half-lives (prealbumin, cholinesterase, retinol-binding protein) and longer half-lives (transferrin, albumin). The latter ones remained constant in both groups during the observation period. As an example of the visceral proteins with short half-lives the time course of retinol-binding protein ( Fig. 3 ) is shown. The initial values of the orally fed patients were again significantly better compared to the PEG patients. But this ratio reversed during the radiotherapeutic course. The PEG patients' values improved steadily, whereas those of the orally fed patients deteriorated significantly at 6 weeks. Nearly the same time course was found for the values of prealbumin and cholinesterase. From the values of the short half-life visceral proteins we conclude that long-term enteral feeding improves the metabolic nutritional status.
The effects of enteral feeding via PEG on patients' quality of life was investigated by the questionnaire of Padilla et al. [6; for details of the questions and their evaluation see Senft et al., 7] . As for the objective parameters, orally fed patients had markedly better initial values before radiotherapy compared to the PEG patients (Fig. 4) . But, as shown by the relative values, during the radiotherapeutic course the values of the orally fed patients dropped by 10-20%. In contrast the PEG patients' values remained constant during this treatment period. The difference at 6 weeks (endpoint of radiotherapy) is significantly different for the two groups. After completion of radiotherapy the values of the orally fed patients slowly recovered.
Mostly tumors in the head and neck region are not treated by radiotherapy alone; i.e. multimodal strategies combining surgery, chemotherapy and external beam/interstitial radiotherapy are used. In order to evaluate the influence of these different modalities, we compared the loss of body weight before and after completion of these therapies (Table 2) . Patients with oral nutrition alone suffered from weight loss which was dependent on the treatment. Following surgery and radiotherapy -the procedure used mostly in early cancer stages in our department -the mean weight loss was 1.0 kg during radiotherapy. Here the weight loss during previous surgery was not taken into account. If additional interstitial radiotherapy was performed, the mean weight loss was 4.0 kg. In our department concurrent or sequential radio(chemo)therapy is used for advanced tumor stages; radiotherapy alone is performed only in patients who, for medical reasons, are not suitable for other treatment modalities. Following these three treatment regimens patients showed serious weight loss of 3.1-5.6 kg. In contrast, patients with PEG had only minor weight loss of 0.3-0.8 kg or put on weight of 0.6-1.8 kg.
Principles of Nutritional Therapy during Radiotherapy
For all patients expected to present nutritional problems in response to radiotherapy the indications and types of nutritional support should be fixed before radiotherapy starts. In principle nutritional support comprises: dietetic counselling; medication; forced oral nutrition; enteral nutrition, and parenteral nutrition (Table 3) . Indications for each type of nutritional support are shown in Table 4 . The nutritional therapy must be adapted to the type and extent of malnutrition as well as to the type of anticancer therapy.
Dietetic counselling must explain to the patients what kind of food is recommended or not (Table 5) during radiotherapy. Most patients with head and neck tumors are excessive smokers and drinkers with bad eating habits, poor oral hygiene and a very bad dental status because of inadequate dental care. These patients must be told that they at least have to change their eating habits, avoid alcohol and smoking during radiotherapy. Appetizing preparation of foods can perhaps help patients with anorexia.
Another way to improve the nutritional status of cancer patients is the supportive use of megestrol acetate during radio(chemo)therapy. In a randomized, double-blind, placebo-controlled study we were able to show that the nutritional status of patients with tumors in the head and neck region as measured by anthropometric and biochemical parameters was improved by megestrol acetate. But the difference between the placebo group and the patients treated with megestrol acetate was most pronounced in patients taking food orally (weight loss during radiotherapy: control group 4.1 kg, megestrol acetate group 0.8 kg; p = 0.0004), but was not significant in patients fed via PEG [8] . New drugs (i.e. thalidomide, melatonin, clenbuterol, anabolic steroids, ˆ-3 fatty acids, anti-TNF antibodies, pentoxyfilline) for the pharmacological treatment of anorexia-cachexia are currently under investigation [4] .
Our results show that ambulatory enteral nutrition via PEG is feasible. Outpatient care by a "nutritional team" operating within a care-providing system serving a wide area has proven highly successful. Nevertheless implantation of PEG is an invasive procedure. In a recent study of 1,299 PEG patients the mortality rate due to the procedure was 0.5%; severe complications (peritonitis, perforation or faulty puncture) occurred in 0.9% [9] . But the long-term positive effects are predominant. Our personal observations and the results of the investigations of the Padilla index showed better subjective well-being ("quality of life") of tumor patients with the help of PEG nutrition. Consequently the indications for initiation of enteral nutrition via PEG are: (1) planned aggressive antitumor therapy, for example radio(chemo)therapy, large-volume and high-dose external beam or interstitial radiotherapy; (2) if extensive surgery of the upper aerodigestive tract interferes with oral nutrition; (3) if mastication or swallowing becomes impossible due to advanced-stage tumor either before therapy or in palliative situations, and (4) weight loss of 1 10% before or during therapy.
Parenteral nutrition directly delivers nutrients into the blood. The gastrointestinal tract is bypassed. Carbohydrates, lipids, amino acids, minerals and vitamins are mixed into a bag to be administered via a pump for different time periods which can be adjusted to the patient's lifestyle. Nevertheless complications affect the patients. The most common complications are clinical infections requiring antibiotic treatment, vein thrombosis, catheter occlusion or shoulder pain. Recent meta-analyses of parenteral nutrition in cancer patients receiving chemotherapy revealed that mortality was increased in patients under parenteral nutrition even when catheter-related septicemia was excluded [10, 11] . Therefore the American College of Physicians [12] did not recommend routine use of parenteral nutrition in cancer patients undergoing chemotherapy. Trials performed from 1979 to 1985 were not able to show a positive effect of parenteral nutrition on patients treated with radiotherapy for abdominal or pelvic cancer [13] [14] [15] . But, of course, the techniques of parenteral nutrition used in these trials cannot be compared to modern standards. Innovative new trials of parenteral nutrition are not available. Therefore our indications for parenteral nutrition from a practical point of view are: (1) if enteral nutrition is not possible or is ineffective, and (2) if a tumor within the upper gastrointestinal tract is treated (i.e. pancreatic cancer, stomach cancer) by radio(chemo)therapy.
Discussion
Dr. Waitzberg: What was the length of stay of the patients you fed by percutaneous endoscopic gastrostomy (PEG)? Were intercurrent infections less in the patients on PEG?
Dr. Fietkau: I mentioned the 10% complication rate because everyone using PEG must realize that it is an invasive procedure, but if you have an effective nutritional team, I think this complication rate can be lowered very markedly. The 10% rate was in our first 1,000 patients. In the second 1,000 the rate is much lower. I think the rate for major complications is now below 1%. Most of the patients are treated as outpatients, and it is difficult to obtain convincing objective data on the effectiveness of this nutritional management. But if you have seen these patients during therapy -and I've seen most of them personally -you realize that they are able to undergo very intensive treatment without breaks and with improved quality if life. We need to consider not only whether patients survive the treatment but how they survive the treatment.
Dr. Benes: When we first read your article about PEG, we liked it very much and determined to do the same thing in our department. However, there was a very low rate of compliance, both from the patients and their physicians. Then we realized that the duration of radiotherapeutic edema is quite short, only 1-3 weeks, and that this was not an indication for PEG. So we decided to nourish the patients by fine bore nasogastric tube before radiotherapy or at the start, when there was no edema. The patients are encouraged to eat normally until the onset of the edema, at which time we start enteral nutrition by the nasogastric tube. We are normally able to stop this after 2-3 weeks. This has been quite successful. Our present strategy is to use PEG only for palliative treatment of outpatients, and not during radiotherapy.
Dr. Fietkau: My question then is, do you use concurrent radiotherapy or do you use postoperative radiotherapy? I agree with you that with postoperative radiotherapy it is generally not necessary to use PEG. But I think nasogastric tubes have some problems, for example they have to pass through the mouth where side effects of radiotherapy, such as mucositis, are common. When we started with PEG my experience was similar to yourscompliance in most patients was rather poor. But when my surgical colleagues on the enteral nutrition team saw the positive effects of PEG feeding, they were convinced, and then we started to install PEGs at the time of the first endoscopic view of the tumor. This resulted in an increase in patient compliance because they had only one invasive procedure.
Dr. Argiles: You told us that you observed an increase in body weight in your group of patients receiving megestrol acetate. Did you measure lean body mass? My second question also concerns megestrol acetate. You said there was no alteration in the quality of life on this treatment, but you also pointed out that some of the patients became impotent. How do you reconcile these two statements?
Dr. Fietkau: In answer to your first question, at the time the studies were done we were unable to measure lean body mass because of technical limitations. With regard to quality of life, this index contains many items and the data presented reflected the average value of these. Of course impotence is important for many men, but there were other variables in the index which improved, so the mean score did not decrease.
Dr. Ottery: There have been a couple of anecdotal reports about tumor seeding at the PEG site when the feeding tube has been pulled through a bulky tumor. It sounds as though you have not seen that in your experience. Second, if you had a very large bulky tumor, would that be a relative contraindication or would you find a different way of putting in a feeding gastrostomy, now that there are a couple of adverse reports? Some people become squeamish when they see reports like that.
I also have a comment. With pancreatic cancers, I think we often don't need to give parenteral nutrition unless the patient is severely affected by nausea and vomiting because of the combined treatment. I think the use of pancreatic enzyme replacement -we give 8,000 units of lipase for every 5-7 g fat -can often get people to stop losing weight. Obviously the earlier you address that component, the less wasting you will have.
Dr. Fietkau: As to your first point, I've never seen implantation of a tumor. I've used PEG for patients with esophageal cancer and I've never seen one there either, so I don't think it's a contraindication. One contraindication may be if you are giving radiochemotherapy just before surgery; then you need to ask your surgeon whether he is happy with PEG under those circumstances. Some are and some aren't. Some surgeons are unhappy about the presence of a PEG if they're using the stomach to fashion an esophagus.
Second, about pancreatic cancer. Effective therapy involves 5-fluorouracil and radiotherapy, and this usually causes severe nausea and vomiting, so it is nearly impossible for patients to eat sometimes. If the patient is unable to eat during therapy, total parenteral nutrition is indicated. There's a different matter from palliative treatment.
Dr. Nitenberg: I'd like to go back to the basic question. What do we want to do with our patients? What do we want to improve in them? If you look at the recommendations of the ASPEN team, they say there is presently no indication for nutritional support for patients receiving chemotherapy or radiotherapy. If we want to fight against that, we have to prove that it is effective. In your study, for example, what data did you obtain exactly? You showed that your patients probably gained weight, but this was fat, not muscle. You show no improvement in morbidity. You show no improvement in mortality. It seems that we need much better defined endpoints to counteract the view that this treatment is unnecessary.
Dr. Fietkau: When we started this work, we wanted to do a prospective randomized trial, but this was not possible for the reasons I gave. Therefore we did an observational study to see how PEG enteral feeding worked in practice. My objective for nutritional therapy is to get the patient through the specific anti-cancer treatment without breaks. It is very hard nowadays to set up a trial where you randomize patients to receive or not receive enteral nutrition. Perhaps this may be possible in other countries. However, if you're giving very intensive therapy, I'm convinced that it is not possible without nutritional support.
Dr. Heimburger: I think we should be under no illusion that we're going to cure cancer or even increase the likelihood of cure by these nutritional procedures. It is possible that avoiding severe malnutrition during therapy would increase our ability to cure cancer and improve long-term survival, but I think that would have been documented by now if it were true. So I think we need now to stop apologizing for using quality of life as an endpoint. One of the reasons for that is that there has been a really significant shift in the nature of being a cancer patient. As curative treatments have become more effective and more cancers are cured, what we have now, as compared with 10 or 20 years ago, is a much larger population of people who are cancer survivors. For these people, quality of life as well as prevention of recurrence are everything. They are becoming more and more sophisticated in the information that they're obtaining, especially from the internet, so the questions they are asking health professionals are also becoming increasingly sophisticated. This should be taken into account as we design trials for concurrent nutritional support during cancer therapy.
We have just inaugurated what we're calling an interdisciplinary supportive care program at the University of Alabama at Birmingham, after a couple of years of planning and some assistance in consultation and good ideas from Dr. Ottery. In this, nutrition is joined with psychiatry, physical medicine, rehabilitation, social work, pastoral care, and the allied health fields associated with these into a single clinical entity that will explicitly address the often overlapping supportive care needs and quality-of-life considerations. For example, many patients don't eat well because they're depressed, and so nutrition interacts with depression, with psycho-oncology; or there may be physical problems with eating related to the location of the tumor, the treatment and so on, so physical medicine rehabilitation comes in there. We are going to gather prospective data and to document the impact on quality of life of this interdisciplinary program.
One last comment I might make is that, while we have had 100% enthusiastic support from our patients, and while surgical and radiation oncologists seem to recognize the need for such an approach, our really uphill struggle has been with the medical oncologists! Dr. Nitenberg: I believe that quality of life is a very good marker, but perhaps it could be made more sophisticated, for example, by considering cost-effectiveness or quality-adjusted life-years, as has been proposed in some studies. I think we need to develop better endpoints for such studies. We are in a time of scarce resources. If we can't prove that what we do is beneficial for patients, we probably will not continue to deserve our jobs. That is the challenge.
Dr. Bachmann: With respect to endpoints, it has been shown that interruption of radiotherapy is associated with a worse prognosis and also that the outcome is worse in malnourished cancer patients who don't receive their full chemotherapy regimen. Do you think completion of treatment could be a good endpoint for a study? If so, we need to be very aware of complications of nutritional treatment, especially with invasive methods like PEG.
Dr. Fietkau: I think completeness of therapy is a very crucial endpoint. That is my primary objective in nutritional therapy; it's not to cure the patient but to make it possible for the patient to receive full curative treatment. As to the side effects of PEG, if you implant the PEG before beginning definitive treatment there are almost no side effects, because any problems can be sorted out before radiochemotherapy is begun. This may involve a delay of 4 or 5 days, but that's not a crucial delay. The crucial thing is that the patients get all the chemotherapy and all the radiotherapy.
Dr. Kho: You showed us tables of foods that are recommendable and not recommendable during radiotherapy. What is the basis for these recommendations?
Dr. Fietkau: These are my personal recommendations, and the recommendations of our institute.
Dr. Kho: Aside from megestrol acetate, are there any pharmacologic interventions that can be useful? For example, what is the role of mucosal protection in patients on radiotherapy?
Dr. Fietkau: Corticosteroids may sometimes be helpful during radiotherapy by reducing the incidence of mucositis, although they are not recommended in the initial period of radiotherapy. Many drugs have been investigated for the management of mucositis but none has been shown to be effective. If all the treatment is completed without breaks, you have to face the fact that the patient will have grade-2 or 3 mucositis.
